摘要
Abstract
Objective:To investigate the efficacy of Rivaroxaban and Warfarin in patients with nonvalvular atrial fibrillation(NVAF).Methods:Clinical data of 60 patients with NVAF admitted to Rizhao City Hospital of Traditional Chinese Medicine from January 2021 to January 2023 were retrospectively analysed.They were divided into a study group and a control group according to different treatment methods.The study group was treated with Rivaroxaban Tablets,the control group was treated with Warfarin Sodium Tablets.The coagulation function,serological indexes,occurrence of hematological abnormalities and adverse reactions were compared between the two groups.Results:After treatment,the activated partial thromboplastin time,prothrombin time and thrombin time of the study group were longer than those of the control group,the fibrinogen level was lower than that of the control group,with statistical significances(P<0.05).After treatment,the levels of D-dimer and N-terminal B-type natriuretic peptide precursors in the study group were lower than those in the control group,with statistical significance(P<0.05).The incidence of abnormal bleeding in the study group was 6.67%,which was lower than 26.67%in the control group,the difference was statistically significant(P<0.05).The incidence of blood embolism in the study group was 6.67%,the incidence of adverse reactions was 16.67%,which had no statistical significance compared with 10.00%and 23.33%in the control group(P>0.05).Conclusion:Rivaroxaban is more beneficial to improve the coagulation function of patients with NVAF,correct the disorder of serological indicators,reduce the incidence of abnormal bleeding,and relatively safe.关键词
非瓣膜性心房颤动/利伐沙班/华法林/凝血功能Key words
Nonvalvular atrial fibrillation/Rivaroxaban/Warfarin/Coagulation function分类
医药卫生
